Donna VineDonna Vine, PhD

Office:      4-002H Li Ka Shing Centre for Health Research Innovation
Mail:         University of Alberta, Edmonton, AB Canada T6G 2E1
Phone:      780-492-4393 (Office)
                780-492-6358 (Lab)
Fax:          780-492-9270
Email:       donna.vine@ualberta.ca

 

 

 

Current Position

Associate Professor
Co-Director, Metabolic and Cardiovascular Diseases Laboratory
Alberta Institute for Human Nutrition
Division of Human Nutrition
Molecular Cell Biology of Lipids
Alberta Diabetes Institute
Mazankowski Alberta Heart Institute

 

Research Area

 

Evaluating the impact of nutrition and chronic disease on intestinal lipid metabolism.

 

Research Goals

We are interested in fundamental and translational aspects of lipid metabolism in nutrition-related chronic diseases. In particular, how dietary (intestinal) derived lipids and their metabolism contribute to, or alleviate pathways that cause cardiovascular etiology.

We are keen to appreciate how the etiology of early obesity, insulin resistance and Type 2 diabetes accelerates CVD complications and influence lipid homeostasis.

Our dynamic and vibrant group fosters a supportive research environment for staff/trainees in order to build capacity and facilitate unique inter-disciplinary scientific training

 

Current Research Activities

Granting Agency:  University of Alberta, Food and Health Innovation Initiative

Title:  Investigation of the beneficial effects of niacin (vitamin B3) to improve atherogenic blood lipid profile, insulin-glucose metabolism and reproductive indices in the JCR:LA-cp rodent model of polycystic ovarian syndrome.
Researcher:  Vine DF (PI)
Start/End Date:  2012-2013
Stage of Project:  Discovery

 

 

Granting Agency:  AARI, ACIDF 

Title:  Plant protein nanoparticles to improve oral bioavailability of bioactive compounds - rodent study.

Researcher:  Chen L (PI), Vine DF + 1 other (Co-PI)
Start/End Date:  2011-2013
Stage of Project:  Translational stage

Granting Agency:  Alberta Livestock and Meat Agency (ALMA)-Research Program
Title:  Translating the Health Benefits of Ruminant Trans Fatty Acids – rodent study
Researcher:  Proctor SD (PI) + Vine DF and 2 other (Co-PI)
Start/End Date:  2011-2013
Stage of Project:  (Multi-Project Grant)  Discovery stage.  (For Clinical Project SEE below ‘clinical’ section for further details).

Granting Agency:  Natural Sciences and Engineering Research Council of Canada (NSERC)-Discovery
Title: The relationship between intestinal lipid transport processes, insulin metabolism and modulation by dietary lipids – rodent study

Researchers:  Vine DF (PI) 
Start/End Dates:  2007-2013
Stage of Project:  Translational stage

 

Human Studies

 

Grant Agency:  Alberta Livestock and Meat Agency (ALMA)-Research Program
Title:  Translating the Health Benefits of Ruminant Trans Fatty Acids.
Researchers:  Proctor SD (PI) + Vine DF and 2 other (Co-PI)
Start/End Dates:  2011-2015

Study Synopsis: (Multi-Project Grant-Clinical Project)  To investigate the impact of a diet enriched in trans-11 vaccenic acid on circulating plasma lipid and apolipoprotein concentrations in hyper-TG male subjects. We have shown that vaccenic acid upregulates lipogenic pathways under conditions of dyslipidemia. Based on this, we anticipate that consumption of vaccenic acid will lead to reduced plasma triglyceride. We also anticipate reductions in total cholesterol and LDL-cholesterol concentration with consumption of vaccenic acid.  To examine the impact of vaccenic acid on inflammation and immune response. We hypothesize that unlike iTFA, when fed a diet enriched in vaccenic acid, MLN cells will produce higher concentrations of the anti-inflammatory cytokine, IL-10, and will reduce inflammation as measured by CRP and CRP production rate.

 

Study Status:  Project is in progress
Contact Info:  Dr. Spencer Proctor, spencer.proctor@ualberta.ca, 780-492-4672

 

Grant Agency:  Canadian Institutes of Health Research-Operating-Clinical
Title:  Hypolipidemic effects of Dietary Trans-11 Vaccenic Acid Supplmentation in Naïve Hyper-Lipidemic Subjects
Researchers:  Proctor SD (PI) and Vine DF and 1 other (Co-PI)
Start/End Date:  2012-2014

Study synopsis:  The primary focus of this proposal is to determine the potential for dietary trans vaccenic acid to improve dyslipidemia in humans. Dyslipidemia is the most common lipid and vascular complication of obesity. This research proposal is a relevant research project as it uses vaccenic acid as an intervention to treat dyslipidemia in obese, with mild hyper-triglyceridemia. It is estimated that obesity-related cardiovascular disease cost the Canadian health system approximately $2.5 billion; the equivalent of 1.3% of total health care costs in Canada. It could be argued that a sedentary lifestyle and a diet high in saturated and industrial trans fats, has fuelled the increasing prevalence of obesity and subsequent cardiovascular disease (CVD) and type 2 diabetes. Although industrial hydrogenated oils (such as elaidic acid) have been associated with dyslipidemia and increased CVD risk, natural ruminant-derived trans fatty acids from dairy sources have not been unequivocally associated with CVD risk. Recent evidence from our group using an animal model of dyslipidemia has revealed that the predominant fatty acid isomer found in ruminant trans fat (trans-11 (18:1) known as vaccenic acid), may actually have hypo-lipidemic and anti-inflammatory health effects.  However, whether vaccenic acid exerts hypo-lipidemic and anti-inflammatory effects in humans with dyslipidemia remains unknown. The primary objective of this study is to investigate the hypo-lipidemic properties and anti-inflammatory effects of a diet supplemented with vaccenic acid (the main 18:1 trans isomer found in dairy products) as a intervention to treat a population of dyslipidemic obese men.

 

Study Status:  Newly awarded grant, preparing for start up.
Contact Info:  Dr. Spencer Proctor, spencer.proctor@ualberta.ca, Telephone: 780-492-4672

 

 

Other Activities and Affiliations

 

Current Membership and Community Representation:

2005-present   Member, Canadian & Alberta Obesity Network

2005-present   Member, Canadian Society Atherosclerosis, Thrombosis and Vascular Biology

(CSATVB)

2005-present   Member, Canadian Society of Clinical Nutrition (CSCN)

2005-present   Scientific Manuscript Reviewer, LIPIDS, Ed. Dr. Thad Rosenberger

2005-present   Scientific Manuscript Reviewer,  New Biotechnology (Lipids), Ed. Dr R Weslake

2006-present   Member, Canadian Lipoprotein Society

2006-present   Member, International Society for Fatty Acids and Lipids

2006-present   Member, The Endocrine Society

2007-present   Co-Director, Metabolic and Cardiovascular Diseases (MCVD) Lab, University of

Alberta

2007-present   Member, University of Alberta SCOLAR and MCBL Group

2007-present   Principle Member, Alberta Diabetes Institute (ADI) and Muttart Diabetes

Research Training Centre

2008-present   Member, Faculty Academic Program, Division Human Nutrition, University of

Alberta; Undergraduate Program Advisor Nutrition Major

2008-present  Member, Nutrition and Food Program Committee, University of Alberta

2008-present  Executive Committee Member, National Nutrition Committee of the Canadian

Diabetes Association (CDA)

2009-present  Executive Member of Board of Directors, Policy Chair, University Childcare and

Early Learning Centre

2010-present   Member, Canadian Nutrition Society (CNS)

2010-present   Advisory Committee Member, Food Regulatory Advisory Committee (FRAC),

Health Canada

 

Biography

 

Dr. Donna Vine trained as a physiologist and biochemistry scientist in both Australia and Canada. She joined the Department of Agricultural, Food and Nutritional Science at the University of Alberta in 2004 and went on to become an Associate Professor in 2011.  Area of focus:  Evaluating the impact of nutrition and chronic disease on intestinal lipid metabolism.

Research Summary

Dr. Vine and the MCVD Laboratory are contributing to the link between intestinal lipid absorption and metabolism in relationship to cardiovascular disease, metabolic syndrome, polycystic ovarian syndrome and pre-diabetes.  Emerging evidence suggest the intestine contributes significantly to whole body cholesterol and triglyceride metabolism, yet there remains a lack of knowledge regarding the regulation of intestinal lipid absorption, and transport of dietary lipids to the circulation via intestinal lipoproteins (chylomicrons).  Dr. Vine and her team (together with Dr. Proctor, Nutrition, UofA) has been one of the first to contribute to the study of the effect of dietary fats on lipid transport and metabolism pathways in these disease states and they continue to research the basic physiological processes involved.  Most recently they have begun to explore dietary improvements and pharmaceutical interventions to understand the etiology of the metabolic complications of PCOS in animal models.  

 

Major Achievements

Research Highlights:

We have made extensive contributions to the study of intestinal chylomicrons, which has lead to the discovery that the impairment of intestinal chylomicron metabolism leads to an accumulation of these particles in the circulation. 
• We have been the first to provide evidence that dietary derived cholesterol oxidation products are rapidly absorbed by the intestine, are incorporated into intestinal chylomicrons and transported to the circulation. 
• We have discovered using intestinal ‘Ussing’ diffusion techniques that dietary type and amount can influence both the histological integrity and the physiological transport processes of the intestine. 
• We developed a novel surgical (in-situ perfusion) and analytical methods (confocal microscopy) to determine the permeability of intestinal chylomicron-remnants into arterial vessels. 
• We have pioneered the development of an animal model to investigate the pathophysiology of Polycystic Ovary Syndrome (PCOS) and the development of insulin resistance and dyslipidemia in PCOS.

 

 

Selected Publications

 

1)        Vine D.F, S. A. Charman, C.J.H. Porter. (2002) Effect of dietary fatty acids on the permeability characteristics of the intestinal BBM in vitro using markers of passive and active transport. Journal Pharmaceutics and Pharmacology;54:809-19.

2)         Proctor SD, Vine DF and Mamo JCL. Arterial retention of apolipoprotein B48 and B100-containing lipoproteins in atherogenesis. Current Opinion in Lipidology.  2002;13(5):461-470,Front Cover Feature. (IF=7.0)

3)         Proctor SD, Vine DF and Mamo JCL. Arterial permeability and efflux of apolipoprotein B containing lipoproteins assessed by in-situ perfusion and three-dimensional quantitative confocal microscopy. Arteriosclerosis, Thrombosis and Vascular Biology.  2004,Jul;(11):2162-2167. (IF=6.8)

4)         Oddy WH, Pal S, Kusel MM, Vine DF, de Klerk NH, Hartmann P, Halt P, Sly P, Burton P, Stanley F and Landau LI (2006). Atopy, eczema and breast milk fatty acids in a high-risk cohort of children followed from birth to 5 yr. Pediatr Allergy Immunol. Feb;17(1):4-10.

5)         Russell JC, Kelly SE, Diane A, Wang Y, Mangat R, Novak S, Vine DF*, Proctor SD*.  Rimonabant-mediated changes in intestinal lipid metabolism and improved vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome.  AJP Gastro and Liver Physiol.  2010 Aug;299(2):G507-16.

6)         Mangat R, Vine DF, Forbes JM, Cooper ME, Mamo JCL and Proctor SD.  Increased risk of cardiovascular disease in type 1 diabetes: arterial exposure to remnant lipoproteins leads to enhanced deposition of cholesterol and binding to glycated extracellular matrix proteoglycans.  Diabetic Medicine.  2011 Jan;28(1):61-72

7)         Lu J, Borthwick F, Hassanali Z, Wang Y, Mangat R, Mangat R, Shi D, Jaeschke A, Russell J, Field CJ, Proctor SD * and Vine DF *.  Chronic dietary n-3 PUFA intervention improves dyslipidemia and subsequent cardiovascular complications in the JCR:LA-cp rat model of the metabolic syndrome.  British Journal of Nutrition (2011), volume 105, issue 11, pp. 1572-1582 (IF=3.4).

8)         Shi D and Vine DF.  Emerging animal models of the endocrine and metabolic disturbances in polycystic ovarian syndrome. Currently being prepared for European Journal Obstetrics and Gynecology.  Accepted and in press 2012.

9)         Vine DF, Bakovic M.  Mechanisms of hypertriglyceridemia in CTP:phosphoethanolamine cytidylyltransferase (Pcyt2) deficient mice.  Journal of Lipid Research.  Accepted and in press 2012.

10)      Mangat R, Warnakula S, Borthwick F, Hassanali Z, Uwiera R, Russell JC, Cheeseman CI, Vine DF and Proctor SD. Arterial retention of remnant lipoproteins ex-vivo is increased during insulin resistance due to increased arterial biglycan and production of cholesterol-rich atherogenic particles, that can be improved by ezetimibe in the JCR:LA-cp rat. Journal of the American Heart Association (open access).  Conditionally accepted 2012.

*authors equal senior authors
As of Nov. 2009:  H-index score=6 and average citation/item= 14.13 (isiknowlege.com)

Trainees

 

Student

Degree or Title

Project Description

Enrolled

Completion Date

Responsibility

Ms. Maria Kupreeva

Summer Student

General laboratory work with a focus on lipid detection in plasma and lymph.

May. 2012

Aug. 2012

Supervisor

Ms. Tina Ullrich

Visiting

PhD

To determine whether the blood lipid-lowering properties of Niacin are a direct result of improvements in intestinal lipid production in the obese and insulin resistant JCR:LA-cp rat model of the metabolic syndrome.

Jan. 2012

Aug. 2012

Co-Supervisor/ U of Leipzig

Ms. Sandra  Kelly

Senior Laboratory Technician

Laboratory Technician

Jan. 2012

Ongoing

Co-Supervisor

Dr. Ye (Flora) Wang

Postdoctoral Fellow

Lipid metabolism in humans.

Jul. 2011

Jun. 2012

Co-Supervisor

Ms. Sheng (Shannon) Wu

MSc

The role of novel red yeast rice formulations to modulate lipid metabolism and reduce dyslipidemia and vascular disease in the JCR:LA-cp rat.

Jan. 2011

Dec. 2012

Co-Supervisor

Ms. Zohre Hashemi

MSc

Dr. Chan, human nutrition research project

Sept. 2010

April 2013

Supervisory or Examination Committee

Ms. Ying Zhou

MSc

Dr. Lingyun Chen, human nutrition research project

 

 

Sept. 2010

April 2013

Supervisory or Examination Committee

Ms. Fatheema Begum

PhD

Dr. Rhonda Bell, human nutrition research project

Sept. 2010

April 2014

Supervisory or Examination Committee

Ms. Lisa Kish

MSc

Dr. Karen Madsen, Gastroenterology medicine research project

Sept. 2009

April 2012

Supervisory or Examination Committee

Ms. Qun Li

MSc

Dr. Tom Clandinin, human nutrition research project

Sept. 2010

April 2013

Supervisory or Examination Committee

Ms. Doaa Dahlawi

MSc

Dr. Rhonda Bell, human nutrition research project

Sept. 2010

April 2014

Supervisory or Examination Committee

Mr. Hamed Gizad

PhD

Dr. Cathy Chan, physiology research project

Sept. 2009

April 2012

Supervisory or Examination Committee

Mr. Homun Yee

BSc

Dr. Cathy Chan, physiology research project

Sept. 2009

April 2012

Supervisory or Examination Committee

Ms. Gayathiri Durai Raj

MSc

Dr. Cathy Chan, human nutrition research project

Sept. 2009

April 2012

Supervisory or Examination Committee

Ms. Stara Morning

Research Coordinator

Program Technician

Apr. 2009

Ongoing

Co-Supervisor

Ms. Alyaa Ibrahim

PhD

Dr. Fakhreddin Jamali, pharmacy research project

Sept. 2008

April 2012

Supervisory or Examination Committee

Ms. Miriam Jacome

PhD

Novel dairy fractionation methodology to improve fat quality for nutritional health

Jan. 2008

July 2012

Co-Supervisor

Ms. Sharon Sokolik

Laboratory Technician        

Animal Technician

Jul. 2004

Ongoing

Co-Supervisor

 

Website Links of Interest

 

MVCD